... or recurrent non-small cell lung cancer receiving PD-1/PD-L1 inhibitor monotherapy. Active and inactive ghrelin levels were measured in 100 patients with available plasma samples at immune checkpoint inhibitor initiation. Cancer cachexia was defined as weight loss of at least 5% during the past 6 months...

... and activity can enhance the osimertinib-induced cytotoxicity in non-small cell lung cancer (NSCLC) cells. Methods: We used the MTS, trypan blue dye exclusion and colony-formation ability assay to determine whether osimertinib alone or in combination with B02 had cytotoxic effects on NSCLC cell lines. Real...

... the molecular-targeting and inhibitory effects of the nanocomposite on non-small cell lung cancer (NSCLC) and liver cancer. Methods: Nanocomposites were prepared using amino-modified iron oxide nanoparticles as carriers, co-loading CDDP and PEGylated FA/TFPI-2. Transmission electron microscopy, UV absorption...

...Jingjing Li; Jinhua Xu; Guofeng Wu; Yajun Ren; Xue Wang; Qianyun Zhang Background: Research suggests that circRNAs play important roles in non-small cell lung cancer (NSCLC). The function of hsa_circ_0068252 in NSCLC, especially in cisplatin (DDP) resistance and the mechanisms, was explored...

...Tonglin Men; Qiaoyan Cui; Yongyu Liu; Shenzhong Zhang Objective: The objective was to study the effectiveness and safety of super-selective bronchial arterial infusion (SBAI) chemotherapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Methods: The clinical data of 120...

...Qinghua Zeng; Xiquan Zhang; Shan He; Zhiyong Zhou; Luping Xia; Wenxiong Zhang; Lin Zeng Background: Crizotinib and alectinib are the 2 most commonly used anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive non-small cell lung cancer (NSCLC). We compared their antitumor efficacies...

...Mie Kotake; Tomohito Kuwako; Hisao Imai; Yoshio Tomizawa; Kyoichi Kaira; Akihiro Yoshii; Mai Ochiai; Yosuke Miura; Takashi Osaki; Reiko Sakurai; Kousuke Takei; Koichi Minato; Ryusei Saito Introduction: Treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC) are poor due...

..., instructions or products referred to in the content or advertisements. 2019 Metastatic melanoma Non-small cell lung cancer Nivolumab Pembrolizumab Atezolizumab The immune checkpoint (ICK) therapy is an emerging approach to oncological treatment, which is increasingly used for a variety...

...Xiaoqin Li; Guomin Gu; Faris Soliman; Andrew J. Sanders; Xiuli Wang; Chunling Liu Background: The overall survival (OS) in non-small cell lung cancer (NSCLC) is poor, with median OS of advanced NSCLC with standard systemic chemotherapy being reported at 13.6 months and the 5-year survival rate...

...Xiaochun Shen; Qiaoming Zhi; Yunliang Wang; Zhi Li; Jin Zhou; Jianan Huang Chemotherapy is widely used in non-small cell lung cancer (NSCLC) treatment, yet multidrug resistance (MDR) is a major chemotherapeutic obstacle in both resectable and advanced NSCLC. Epidermal growth factor-like domain 7...

...Saiama N. Waqar; Maria Q. Baggstrom; Daniel Morgensztern; Kristina Williams; Caron Rigden; Ramaswamy Govindan Background: Pemetrexed is an antifolate chemotherapeutic agent approved for use in non-small cell lung cancer (NSCLC). The mammalian target of rapamycin (mTOR) pathway is implicated in lung...

... of the participating institutions. Each patient signed a written, informed consent according to the protocol. Non-small cell lung cancer S-1 Elderly patients Phase II study Patients with histologically or cytologically documented NSCLC were candidates for this study. Other eligibility criteria included...

... pathological stage IB to IIIA non-small cell lung cancer, who were treated with S-1 postoperatively, were analyzed. The prognostic impacts of 22 clinicopathological factors including expressions of the 5-FU pathway enzymes were evaluated. A single-nucleotide polymorphism (SNP), i.e. 538G>A (rs17822931...

... non-small cell lung cancer (NSCLC). Methods: We reviewed elderly patients with advanced NSCLC who had disease progression after one or more chemotherapy regimens, at least one including platinum, and then who were treated with GV as the salvage therapy. Results: In total 40 patients were analyzed. GV...

... with untreated, advanced, non-small cell lung cancer (NSCLC) was conducted. Amrubicin was given on days 1-3, with nedaplatin given on day 1. The treatment was repeated every 3 weeks. In the phase I trial, the initial amrubicin dose of 25 mg/m 2 was escalated in 5-mg/m 2 increments until the maximum tolerated...

... with unresectable (stages IIIB-IV) non-small cell lung cancer (NSCLC). Methods: In this study, 48 high-risk patients with previously untreated locally advanced or metastatic NSCLC were treated with combination chemotherapy consisting of docetaxel 40 mg/m 2 and cisplatin 40 mg/m 2 ; both drugs were given biweekly...

...Satoshi Igawa; Jiichiro Sasaki; Mikiko Ishihara; Sakiko Otani; Sachiyo Maki; Yasuhiro Hiyoshi; Masashi Kasajima; Ken Katono; Akira Takakura; Noriyuki Masuda Background: Currently, there are no standard cytotoxic treatments for non-small-cell lung cancer (NSCLC) patients beyond third-line therapy...

...M. Früh; H. Besrour; S. Gillessen; M. Joerger; F. Hitz; A. Savidan; T. Cerny; S. Ess Background: Optimal management of elderly patients (≥70 years) with non-small cell lung cancer (NSCLC) remains debatable. We compared survival and treatment of advanced NSCLC between elderly and younger patients...

...Saiama N. Waqar; Priya K. Gopalan; Kristina Williams; Siddhartha Devarakonda; Ramaswamy Govindan Background: Sunitinib is an oral multitargeted tyrosine kinase inhibitor, with single-agent activity in non-small cell lung cancer (NSCLC). Resistance to tyrosine kinase inhibitor therapy is mediated...

...Nana Aono; Yuri Ito; Kazumi Nishino; Junji Uchida; Toru Kumagai; Yuki Akazawa; Takako Okuyama; Tetsuhiro Yoshinami; Fumio Imamura Background: Recently, multiple-line chemotherapy has become popular for non-small cell lung cancer (NSCLC). The survival time of patients is influenced by patient...